Sign up to save your podcasts
Or
Share ONCOLOGY: Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ONCOLOGY: Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
Oncology, December 13th, 2007
Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
STEPHEN JONES, US Oncology Research, Houston
REFERENCE: ABSTRACT 12
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.
View all episodes
By Audio MedicaOncology, December 13th, 2007
Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
STEPHEN JONES, US Oncology Research, Houston
REFERENCE: ABSTRACT 12
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.